Wound Care Fraud Defense &
Skin Substitute Fraud Defense
Former DOJ Fraud Section Prosecutors. Nationwide Defense for Wound Care Providers, Skin Substitute Distributors, Physicians, Nurse Practitioners, and Healthcare Executives Facing Federal Wound Care Fraud Investigations and Charges.
Based in Washington, D.C., Armstrong & Bradylyons PLLC defends wound care providers, skin substitute and cellular tissue-based product (CTP) distributors, physicians, nurse practitioners, sales representatives, healthcare executives, and other individuals in federal wound care fraud investigations and cases nationwide.
The firm’s healthcare fraud defense practice is built on nearly a decade of combined experience at the nation’s preeminent healthcare fraud enforcement unit: the Healthcare Fraud Unit of DOJ’s Fraud Section. Scott Armstrong, Drew Bradylyons, and Andrea Savdie tried 17 federal jury trials in healthcare fraud cases at DOJ’s Fraud Section involving over $2.8 billion in alleged false and fraudulent claims to federal healthcare programs. The firm uses that experience to defend wound care providers and their owners, executives, and employees at every stage of a federal case: from the first audit or grand jury subpoena, through federal indictment, and at trial.
Wound care fraud is a named DOJ enforcement priority. The firm defends individuals in the districts where wound care enforcement is most active: the District of Arizona, the Southern District of Florida, the Southern District of Georgia, Strike Force districts including the Central District of California, the Southern District of Texas, and the Eastern District of New York, and federal courts across the country.
Armstrong & Bradylyons PLLC defends every wound care fraud case from the start as if it will go to trial. That is not a slogan. It is the operating principle of the firm, grounded in 25 federal jury trials in complex fraud cases in federal courts across the country.
Trial experience drives results at every stage. Wound care fraud cases are technically complex. They involve skin substitute product classification and billing, Q code reimbursement structures, rebate and distributor arrangements, debridement coding disputes, clinical documentation for medical necessity, and allegations involving the financial relationships between manufacturers, distributors, and treating providers. The firm builds the factual record from the first day of engagement: analyzing claims data, retaining wound care clinical experts, identifying and preparing witnesses, and developing a case theory that can withstand the government’s scrutiny.
The firm’s attorneys know how federal prosecutors build healthcare fraud cases because they built them. Scott Armstrong served for nearly a decade at DOJ’s Fraud Section, where he served as lead trial counsel in 16 federal jury trials, including complex healthcare fraud cases involving Medicare, Medicaid, and Tricare. Scott also directed DOJ’s Appalachian Regional Prescription Drug Task Force. Drew Bradylyons served as Chief of EDVA’s Financial Crimes and Public Corruption Unit and, before that, supervised the Healthcare Fraud Unit’s Miami Strike Force at DOJ’s Fraud Section. That combined experience provides the firm with an unmatched understanding of how federal healthcare fraud cases are investigated, charged, and tried.
The firm relishes the opportunity to try cases. Its willingness to go to trial and its proven skills at trial provide significant leverage in negotiations with federal prosecutors at every stage of a wound care fraud case.
Wound care fraud is one of the most aggressively prosecuted categories of federal healthcare fraud in 2025 and 2026. DOJ has publicly stated that there are many more skin substitute cases in the pipeline. The enforcement wave is not cresting. It is accelerating.
Medicare Part B spending on skin substitutes exploded from $256 million in 2019 to over $10 billion by the end of 2024. Prices for some products reached more than $2,000 per square centimeter. HHS-OIG issued a September 2025 report that deemed skin substitutes “particularly vulnerable to questionable billing and fraud schemes.” The report identified patterns including multiple claims submitted on the same date to stay below automated denial thresholds, billing by clinicians in specialties unrelated to wound care, use of skin substitutes without prior conservative treatment, and discrepancies between manufacturer-reported sales volumes and units billed to Medicare.
The criminal enforcement has been historic. In the first prosecution of its kind, the owners of Arizona wound graft marketing company Apex Medical, LLC were sentenced to 14.5 and 15 years in prison for causing over $1.2 billion in false claims to be submitted to Medicare for medically unnecessary amniotic wound allografts. One defendant admitted receiving $279 million in kickbacks from a wholesale graft distributor, often in the form of non-compliant rebates. Those kickbacks funded commissions to sales representatives who identified elderly patients and ordered unnecessarily large grafts. The scheme resulted in large grafts applied to small wounds, multiple grafts applied to single wounds, grafts applied to non-existent wounds, and grafts applied to terminally ill patients who died on the same day of application. Apex also agreed to pay $309 million to resolve its False Claims Act liability.
On the civil side, DOJ settled with Vohra Wound Physicians Management LLC for $45 million in November 2025. Vohra, one of the nation’s largest providers of bedside wound care for nursing home and skilled nursing facility patients, was accused of billing Medicare for medically unnecessary surgical debridement procedures and upcoding. DOJ alleged that Vohra programmed its proprietary electronic health record system to ensure that Medicare was always billed for the higher-reimbursed surgical excisional debridement code, regardless of the procedure actually performed. DOJ also alleged that Vohra pressured physicians to meet revenue-based debridement quotas. Vohra entered into a five-year Corporate Integrity Agreement with HHS-OIG that included a novel provision requiring independent review of its EHR systems.
In response to the enforcement findings, CMS finalized a fundamental restructuring of the Medicare reimbursement model for skin substitutes in its CY 2026 Physician Fee Schedule Final Rule, effective January 1, 2026. CMS reclassified most skin substitute products from “biologicals” reimbursed under the average sales price (ASP) methodology to “incident-to” supplies reimbursed at a flat rate of approximately $127.28 per square centimeter. CMS estimated that this change would reduce Medicare spending on skin substitute services by $19.6 billion in 2026. The CMS Fraud Defense Operations Center stopped nearly $185 million in improper skin substitute payments in 2025 alone.
Wound care providers, skin substitute distributors, physicians, nurse practitioners, sales representatives, and healthcare executives face real and immediate exposure to federal criminal and civil enforcement. The combination of historic criminal sentences, major FCA settlements, the HHS-OIG report, and the CMS reimbursement restructuring signals that wound care fraud enforcement will intensify further in 2026 and beyond.
The firm’s wound care fraud defense practice is built on healthcare fraud trial experience, command of Medicare skin substitute billing rules and reimbursement structures, and years of experience investigating and prosecuting complex healthcare fraud cases at DOJ’s Fraud Section. These tools are deployed at every phase of a case.
Challenging the Government’s Billing and Utilization Analysis
Federal wound care fraud cases are built on Medicare claims data. The government identifies providers with high volumes of skin substitute applications, billing patterns that diverge from peer averages, high per-patient reimbursement amounts, and claims for products billed at quantities that appear disproportionate to wound size. The firm challenges the government’s data at every level: the selection of comparators, the methodology used to identify outliers, the assumptions underlying utilization analyses, and the conclusions drawn from aggregate billing patterns. Billing for clinically appropriate wound care products is not fraud. The firm ensures that distinction is drawn clearly and forcefully.
Medical Necessity and Wound Care Documentation Defense
The government’s case often hinges on the claim that skin substitutes were not medically necessary, that conservative treatment was not attempted before skin substitute application, or that the wound did not warrant the size or quantity of product billed. The firm retains qualified wound care physicians and clinical experts to review patient records, wound measurements, clinical photographs, and treatment histories. These experts can establish that the prescribed treatment was clinically appropriate, that the patient met applicable CMS coverage criteria and Local Coverage Determination requirements, and that the wound’s characteristics justified the product and quantity applied.
Q Code Billing, Reimbursement Structures, and Rebate Defense
Wound care billing involves a complex intersection of HCPCS Q codes (Q4100 through Q4397 for skin substitutes and biologicals), CPT application codes, CMS product classification categories, and the evolving reimbursement methodology. Before 2026, providers could bill separately for the application procedure and the product at the product’s ASP-based rate, creating a “spread” between acquisition cost and reimbursement that the government now scrutinizes as a driver of overutilization. The firm analyzes applicable billing rules, product classification, and reimbursement structures to challenge the government’s theory that billing practices were fraudulent rather than compliant with the rules as they existed at the time.
Distributor Rebates, Manufacturer Arrangements, and AKS Defense
The financial relationships between skin substitute manufacturers, wholesale distributors, and treating providers are at the center of federal wound care fraud enforcement. The government targets rebate structures in which distributors provide discounts, volume-based rebates, or other financial incentives to providers in exchange for ordering specific products. Prosecutors characterize these arrangements as kickbacks under the Anti-Kickback Statute. The firm challenges the government’s characterization and establishes that the arrangement complied with applicable OIG Safe Harbor Regulations, including the discount safe harbor and the group purchasing organization safe harbor, or that the provider lacked the requisite intent to violate the statute.
Federal wound care fraud investigations target individuals at every level of the supply and treatment chain: from the providers and executives who operate wound care practices, to the physicians and nurse practitioners who treat patients and apply products, the distributors and sales representatives who supply and market skin substitutes, and the manufacturers whose rebate and pricing structures are under scrutiny. Armstrong & Bradylyons PLLC defends these individuals in federal investigations, after indictment, and at trial.
Defense of Wound Care Practice Owners and Executives
The firm defends the founders, owners, and executives of wound care practices, mobile wound care companies, and wound care management organizations in federal fraud, Anti-Kickback Statute, and money laundering investigations and prosecutions. Wound care practice owners are high-priority targets. Prosecutors pursue owners who allegedly directed the application of medically unnecessary skin substitutes, designed compensation structures that incentivized overutilization, manipulated EHR systems to inflate billing, accepted kickbacks from distributors, or set revenue-based treatment quotas for treating clinicians. The firm defends practice owners by challenging the government’s evidence of personal knowledge, direction, and intent.
Defense of Physicians and Nurse Practitioners
The firm defends physicians, nurse practitioners, and podiatrists who treat wounds and apply skin substitute products in federal investigations and cases. Treating clinicians face criminal exposure when the government alleges that they applied products that were not medically necessary, applied products to wounds that did not meet coverage criteria, failed to attempt conservative treatment before skin substitute application, upcoded debridement procedures, or received compensation tied to treatment volume or revenue targets. The firm defends treating clinicians by challenging the government’s clinical evidence and establishing the legitimate medical basis for the clinician’s treatment decisions.
Defense of Skin Substitute Distributors and Sales Representatives
The firm defends wholesale distributors, sales representatives, and independent marketing agents in federal wound care fraud investigations and cases. Distributors and sales representatives face criminal exposure when the government alleges that they paid kickbacks to providers in the form of rebates, discounts, volume-based incentives, or other financial arrangements in exchange for product orders. The Apex prosecution demonstrated that the government will pursue distributor kickback arrangements as the foundation of a massive criminal fraud case. The firm defends distributors and sales professionals by challenging the government’s characterization of commercial arrangements as illegal kickbacks and establishing compliance with applicable safe harbor protections.
Defense of Medical Directors
The firm defends medical directors of wound care practices and skilled nursing facilities in federal investigations. Medical directors face exposure when the government alleges that their directorship fees were structured as kickbacks tied to referral volume, that they supervised or approved treatment that was not medically necessary, or that they failed to exercise independent clinical judgment over treatment decisions. The firm defends medical directors by challenging the government’s evidence and establishing the fair market value and legitimate scope of the directorship arrangement.
Defense of Healthcare Executives and Investors
The firm defends healthcare executives, management services organization (MSO) operators, and investors in wound care companies. Federal prosecutors and the False Claims Act are reaching individuals beyond the direct treatment providers: corporate executives who set treatment quotas, MSO operators who designed billing systems, and investors who exercised operational control over wound care practices. The firm defends these individuals against fraud, conspiracy, money laundering, and kickback charges arising from the operations of wound care organizations.
Federal wound care fraud investigations follow a pattern. Understanding that pattern is the first step to defending against it. Scott Armstrong and Drew Bradylyons built these types of cases as senior prosecutors at DOJ’s Fraud Section. They know how federal investigators identify targets, develop evidence, and present cases to grand juries.
Claims Data Analytics and Product Utilization Review
The investigation typically begins with data. HHS-OIG, CMS, and the FBI use claims data analytics to identify wound care providers with billing patterns that deviate from industry norms. The government flags providers with unusually high volumes of skin substitute applications, per-patient reimbursement rates that far exceed peer averages, billing for quantities of product disproportionate to wound size, multiple claims submitted on the same date to avoid automated denial thresholds, billing by clinicians in specialties unrelated to wound care, and discrepancies between manufacturer-reported sales volumes and the units billed to Medicare. The CMS Fraud Defense Operations Center and the Health Care Fraud Data Fusion Center deploy AI-driven analytics to detect these patterns in real time.
Q Code Billing and Reimbursement Analysis
Federal investigators analyze the specific HCPCS Q codes billed for skin substitute products. The Q code range Q4100 through Q4397 covers skin substitutes and biologicals. The government examines whether the Q code billed corresponds to the product actually applied, whether the quantity billed is supported by wound measurements and clinical documentation, and whether the reimbursement amount reflects the product’s actual acquisition cost or an inflated price. Under the pre-2026 reimbursement model, providers billed for products at the ASP-based rate plus a markup. The “spread” between the provider’s acquisition cost and the Medicare reimbursement created a financial incentive to select higher-priced products. The government uses this spread as evidence that product selection was driven by financial incentive rather than clinical judgment.
Distributor Rebate and Kickback Analysis
The government investigates the financial relationships between skin substitute manufacturers, wholesale distributors, and treating providers. Prosecutors focus on rebate structures in which distributors provide volume-based discounts, free product, marketing support payments, or other financial incentives to providers. The government characterizes these arrangements as kickbacks when the rebate is tied to the volume or value of product ordered and billed to Medicare. The Apex prosecution established that hundreds of millions of dollars in “non-compliant rebates” from a wholesale distributor constituted illegal kickbacks under the Anti-Kickback Statute. Investigators trace the flow of funds between manufacturers, distributors, and providers using financial records, bank statements, and electronic communications.
EHR and Billing System Analysis
The government investigates whether wound care providers used electronic health record (EHR) systems and billing software to facilitate fraudulent billing. The Vohra prosecution established that DOJ will target providers who program EHR systems to automatically select higher-reimbursed procedure codes, restrict clinical documentation options to support upcoded claims, or auto-populate billing fields that do not reflect the actual procedure performed. The DOJ-HHS FCA Working Group has identified manipulation of electronic health records as a priority enforcement area. Investigators analyze EHR metadata, audit logs, and software configuration to identify automated upcoding and documentation manipulation.
Patient and Employee Interviews
Federal agents interview current and former employees, patients, patients’ family members, nursing facility staff, and referral sources. They look for cooperating witnesses who can testify about the provider’s actual treatment practices: whether wounds warranted the products applied, whether products were applied to non-existent or healing wounds, whether documentation was fabricated or exaggerated, whether clinicians were pressured to meet treatment quotas, and whether distributors paid kickbacks for product orders. Cooperating witnesses are a cornerstone of federal wound care fraud prosecutions.
Search Warrants for Electronic Devices and Cloud Accounts
Federal agents routinely seek and execute search warrants for cell phones, laptops, tablets, and cloud-based accounts in wound care fraud investigations. These warrants target communications between practice owners, distributors, sales representatives, and treating clinicians that reveal knowledge of medically unnecessary applications, directives to apply specific products for financial rather than clinical reasons, discussions about rebate arrangements, and efforts to conceal conduct from auditors or regulators. Federal agents obtain cloud warrants under 18 U.S.C. § 2703 of the Stored Communications Act and serve them directly on Apple, Google, and other service providers.
Whistleblower Lawsuits
A significant number of federal wound care fraud investigations originate from qui tam whistleblower lawsuits filed under the False Claims Act. The Apex criminal prosecution grew out of still-sealed qui tam allegations. DOJ has also demonstrated its willingness to file wound care FCA complaints on its own initiative, without a relator, as it did in the Vohra case. Employees, former employees, and competitors who observe potentially fraudulent billing or kickback arrangements can file sealed complaints. DOJ investigates while the case remains under seal. Wound care providers should be aware that nearly 1,300 new qui tam lawsuits were filed in FY 2025.
Federal wound care fraud enforcement is concentrated in specific districts with high volumes of skin substitute billing and established healthcare fraud infrastructure. Armstrong & Bradylyons PLLC defends wound care providers in every one of these jurisdictions.
District of Arizona
Arizona is the site of the Apex Medical prosecution, the largest criminal wound care fraud case in DOJ history. The owners were sentenced to 14.5 and 15 years in prison for causing over $1.2 billion in false claims for medically unnecessary amniotic wound allografts and receiving hundreds of millions in distributor kickbacks. Apex also agreed to pay $309 million to resolve its FCA liability. The District of Arizona is a focal point for wound care enforcement.
Southern District of Florida
The Southern District of Florida is home to one of the most active Medicare Fraud Strike Force teams in the country. The Vohra FCA complaint was filed in the Southern District of Florida, and the $45 million settlement was resolved there. South Florida has a long history of healthcare fraud enforcement and a high volume of wound care billing activity. The district’s experienced federal prosecutors make it a high-risk jurisdiction for wound care providers.
Southern District of Georgia
The Southern District of Georgia participated in the coordinated Vohra resolution alongside the Southern District of Florida. The district has seen increasing wound care enforcement activity as DOJ expands its scrutiny beyond the traditional Strike Force cities.
Central District of California
The Central District of California is a Strike Force district with significant wound care enforcement activity. California accounts for a disproportionate share of national skin substitute billing. CMS and DOJ have publicly announced intensified investigations of healthcare billing fraud in California, including wound care and skin substitute claims.
Southern District of Texas
The Southern District of Texas is a Strike Force district with an aggressive healthcare fraud enforcement posture. Texas is a large wound care market, and the district has experienced prosecutors with healthcare fraud trial experience. Wound care providers operating in Texas face exposure from both Strike Force prosecutors and CMS program integrity contractors.
Additional Districts
Wound care fraud enforcement is not limited to the districts above. DOJ has publicly stated that many more skin substitute cases are in the pipeline. The DOJ-HHS FCA Working Group has identified skin substitute pricing, kickbacks for DME and pharmaceuticals, and EHR manipulation as priority enforcement areas. Federal enforcement activity in wound care is expanding rapidly across the country. Scott Armstrong and Drew Bradylyons defend wound care providers in every federal district where DOJ, CMS, and HHS-OIG bring wound care fraud cases.
Federal wound care fraud prosecutions draw on several criminal statutes. The charges carry severe penalties. Understanding the statutory framework is essential to mounting an effective defense.
Healthcare Fraud (18 U.S.C. § 1347)
The primary charging statute in wound care fraud cases. Healthcare fraud makes it a federal crime to knowingly and willfully execute or attempt to execute a scheme to defraud any healthcare benefit program. In wound care cases, this statute targets billing for medically unnecessary skin substitutes, billing for products applied to non-existent or healing wounds, upcoding debridement procedures, and billing for skin substitutes at inflated prices. The penalty is up to 10 years of imprisonment per count. If the fraud results in serious bodily injury, the maximum increases to 20 years. If it results in death, a life sentence is possible.
Wire Fraud (18 U.S.C. § 1343)
The government frequently charges wire fraud alongside or as an alternative to healthcare fraud. Wire fraud applies to any scheme to defraud that uses interstate wire communications, which includes the electronic submission of Medicare claims. Wire fraud carries a maximum penalty of 20 years of imprisonment per count.
Anti-Kickback Statute (42 U.S.C. § 1320a-7b)
The Anti-Kickback Statute is at the center of federal wound care fraud enforcement. It prohibits offering, paying, soliciting, or receiving anything of value to induce or reward the referral of patients for services covered by federal healthcare programs. In wound care cases, prosecutors target rebates and volume-based discounts from distributors to providers, commissions paid to sales representatives for product orders, payments to patient recruiters for identifying patients with wounds, and medical directorship fees structured as disguised kickbacks. The Apex prosecution demonstrated that distributor rebates characterized as “non-compliant” constitute illegal kickbacks with devastating criminal consequences. Violations carry up to 10 years of imprisonment per violation.
Money Laundering (18 U.S.C. §§ 1956, 1957)
Money laundering charges are common in wound care fraud prosecutions involving large-scale schemes. The government charges money laundering when it alleges that defendants conducted financial transactions involving the proceeds of the fraud scheme with the intent to conceal or promote the underlying fraud. In the Apex case, fraud proceeds were used to purchase gold coins, luxury vehicles, and real estate. Money laundering carries up to 20 years of imprisonment per count.
False Claims Act (31 U.S.C. §§ 3729–3733)
The False Claims Act is the government’s primary civil enforcement tool. It imposes liability on any person who knowingly submits or causes the submission of false or fraudulent claims to the government. In wound care cases, the FCA targets claims for medically unnecessary skin substitutes, upcoded debridement procedures, and claims tainted by kickback relationships. Penalties include treble damages and per-claim penalties. DOJ has demonstrated its willingness to file wound care FCA complaints on its own initiative and to pursue qui tam whistleblower cases. FCA settlements in this space have reached $309 million (Apex) and $45 million (Vohra).
Federal Program Exclusion and Collateral Consequences
Beyond incarceration and fines, a conviction or settlement in a wound care fraud case triggers mandatory exclusion from Medicare, Medicaid, and all federal healthcare programs under the authority of HHS-OIG. Corporate Integrity Agreements, such as the five-year CIA imposed on Vohra, impose ongoing compliance monitoring, independent review of EHR systems, and executive certification requirements. For physicians and nurse practitioners, exclusion effectively ends the ability to bill any federal healthcare program. State licensing boards may also initiate independent disciplinary proceedings.
What Should I Do If I Am Under Investigation for Wound Care Fraud?
Retain experienced federal defense counsel immediately. Do not speak with federal agents, CMS auditors, UPIC contractors, HHS-OIG investigators, or anyone else about the investigation before consulting a defense attorney.
Federal wound care fraud investigations frequently begin with a CMS prepayment review or UPIC audit, a grand jury subpoena, agent contact from the FBI or HHS-OIG, a qui tam whistleblower lawsuit that is later unsealed, or notice of a DOJ Civil Investigative Demand. What you say and produce in the early stages of an investigation shapes the entire case.
Scott Armstrong and Drew Bradylyons defend wound care providers at the investigation stage and at trial, drawing on years of experience as senior prosecutors at DOJ’s Fraud Section.
What Are Q Codes and Why Do They Matter in Wound Care Fraud Cases?
Q codes are HCPCS Level II codes used to bill Medicare for skin substitute and cellular tissue-based products (CTPs). The relevant range is Q4100 through Q4397. Each Q code corresponds to a specific product or product category. Q4100 is the catch-all code for “skin substitute, not otherwise specified.” When billing under Q4100, the provider must report the product name, package size purchased, amount applied, and amount wasted in the claim narrative.
Federal investigators analyze Q code billing to determine whether the product billed matches the product applied, whether the quantity billed is consistent with the wound measurements documented in the medical record, and whether the provider billed under Q4100 to obscure the identity of the product or avoid product-specific scrutiny. The government also examines whether providers selected higher-priced products that generated a larger “spread” between the product’s acquisition cost and the ASP-based Medicare reimbursement. Starting January 1, 2026, CMS replaced the ASP-based reimbursement model with a flat rate of approximately $127.28 per square centimeter for most products, eliminating the spread that drove product selection incentives under the prior model.
What Are the Penalties for a Federal Wound Care Fraud Conviction?
The penalties are severe. Healthcare fraud (18 U.S.C. § 1347) carries up to 10 years of imprisonment per count. Wire fraud carries up to 20 years per count. Money laundering carries up to 20 years per count. Anti-Kickback Statute violations carry up to 10 years per violation.
Beyond incarceration, defendants face substantial fines, restitution orders, and forfeiture of assets. Federal law mandates exclusion from Medicare, Medicaid, and other federal healthcare programs upon conviction. The Apex owners were sentenced to 14.5 and 15 years in prison, ordered to pay over $1.2 billion in restitution, and agreed to $309 million in FCA liability. The Vohra settlement was $45 million with a five-year Corporate Integrity Agreement.
How Do Distributor Rebates Create Anti-Kickback Statute Exposure?
The financial relationships between skin substitute distributors and treating providers are a primary enforcement target. When a distributor provides a rebate, discount, or other financial incentive to a provider in connection with the provider’s ordering and billing of the distributor’s products to Medicare, the government may characterize that arrangement as an illegal kickback under the Anti-Kickback Statute.
The Apex prosecution established the government’s theory in this space. One defendant admitted receiving $279 million in kickbacks from a wholesale graft distributor, often in the form of “non-compliant rebates.” A jointly owned company received an additional $130 million from the same distributor. The government views rebates tied to ordering volume as inducements to order and bill products that may not be medically necessary.
Not all rebates are illegal. The OIG Safe Harbor Regulations provide protection for certain discount and group purchasing arrangements that meet specific requirements. A defense attorney experienced in wound care fraud can evaluate whether a rebate arrangement qualifies for safe harbor protection or whether the arrangement can be defended on other grounds.
How Has the CMS Reimbursement Change Affected Wound Care Fraud Enforcement?
Before January 1, 2026, most skin substitutes were reimbursed under the average sales price (ASP) methodology. Providers could bill separately for the product at the product-specific ASP-based rate plus a markup. This created a “spread” between the provider’s acquisition cost and the Medicare reimbursement that incentivized the selection of higher-priced products.
The CY 2026 Medicare Physician Fee Schedule Final Rule reclassified most skin substitutes from “biologicals” to “incident-to” supplies, reimbursed at a flat rate of approximately $127.28 per square centimeter regardless of the specific product. CMS estimated this change would reduce Medicare spending on skin substitute services by $19.6 billion in 2026.
The reimbursement change does not reduce enforcement risk. The government is actively investigating conduct that occurred under the prior reimbursement model. Providers who billed under the ASP-based system face retrospective scrutiny for product selection driven by financial incentive rather than clinical judgment. The prior reimbursement structure is itself evidence in the government’s theory of the case.
What Wound Care Documentation Does the Government Scrutinize?
Federal investigators focus on specific clinical and billing documentation in wound care cases. The government scrutinizes wound measurements and clinical photographs, documentation of conservative treatment attempted before skin substitute application, vascular assessments (ankle-brachial index, toe pressures), clinical rationale for product selection and quantity applied, debridement procedure notes including the type and extent of debridement performed, and documentation supporting Modifier 25 usage for evaluation and management services billed alongside surgical procedures.
Investigators also examine EHR metadata, including when notes were created, whether documentation was templated or copy-and-paste, and whether the EHR system was configured to auto-select higher-reimbursed procedure codes. The Vohra prosecution established that DOJ will target providers whose EHR systems are designed to restrict clinical documentation and facilitate automated upcoding.
What Defenses Are Available in a Federal Wound Care Fraud Case?
The available defenses depend on the specific allegations. Common defenses in wound care fraud cases include the following:
Medical necessity. Defendants can challenge the government’s claim that skin substitutes were not medically necessary. Wound measurements, clinical photographs, treatment histories, and expert testimony from wound care physicians support this defense.
Lack of intent to defraud. The government must prove willful and knowing fraud. Billing under the ASP-based reimbursement model as it existed at the time, reliance on CMS coverage criteria, and good faith product selection are not crimes.
Safe harbor compliance. In kickback cases, the defense can demonstrate that distributor rebate arrangements complied with applicable OIG Safe Harbor Regulations, including the discount safe harbor, the group purchasing organization safe harbor, or the personal services safe harbor.
Challenging data analysis. The government relies heavily on claims data analytics. Aggregate billing patterns do not prove fraud at the individual patient level. The firm challenges the government’s statistical methodology and its extrapolation calculations.
Scott Armstrong and Drew Bradylyons leverage their significant federal trial experience as former prosecutors to anticipate the government’s trial strategy and develop an aggressive, evidence-based defense.
What Is the Difference Between a Civil and Criminal Wound Care Fraud Investigation?
Civil wound care fraud investigations focus on recovering money. These may involve False Claims Act actions, Civil Investigative Demands (CIDs), and penalties including treble damages and per-claim fines. Many civil wound care fraud cases originate from qui tam whistleblower lawsuits.
Criminal wound care fraud investigations focus on proving intentional and willful fraud beyond a reasonable doubt. Criminal cases carry the possibility of imprisonment, criminal fines, and restitution.
The government frequently runs civil and criminal investigations in parallel. The Apex case involved both criminal guilty pleas with sentences of 14.5 and 15 years and a $309 million civil FCA settlement. Statements and concessions made in a civil matter or audit response can be used to build a criminal case. Scott Armstrong and Drew Bradylyons have years of experience navigating parallel civil and criminal healthcare fraud cases at DOJ’s Fraud Section and as defense attorneys.
Can a Wound Care Practice Owner Be Held Personally Liable for Fraud?
Yes. Federal prosecutors regularly pursue wound care practice owners and executives for fraud committed within their organizations. The owner does not need to have personally applied skin substitutes or submitted false claims. If a provider causes another person to submit a claim with knowledge that the claim is false or fraudulent, a criminal case against that provider may be viable.
The government relies on theories of conspiracy (18 U.S.C. § 371) and aiding and abetting (18 U.S.C. § 2) to reach individuals who directed or designed the fraudulent scheme. Prosecutors also target owners who set revenue-based quotas, designed EHR systems to facilitate upcoding, or accepted kickbacks from distributors.
Why Is Wound Care Fraud Under Intensified Federal Scrutiny Now?
Several factors converged. Medicare Part B spending on skin substitutes exploded from $256 million in 2019 to over $10 billion by 2024. HHS-OIG issued a September 2025 report identifying skin substitutes as “particularly vulnerable” to fraud. The Apex criminal prosecution and $309 million FCA settlement were the largest wound care fraud enforcement actions in DOJ history. The Vohra $45 million settlement targeted EHR manipulation and debridement upcoding. CMS restructured the reimbursement model to eliminate the pricing spread that drove overutilization.
DOJ has publicly stated that many more skin substitute cases are in the pipeline. The DOJ-HHS FCA Working Group has identified skin substitute pricing, kickbacks, and EHR manipulation as priority enforcement areas. The enforcement cycle for wound care fraud is in its early stages, not its final phase.
Does Armstrong & Bradylyons PLLC Handle Wound Care Fraud Cases Outside of Washington, D.C.?
Yes. Armstrong & Bradylyons PLLC defends individuals in federal wound care fraud investigations and prosecutions nationwide. The firm can practice in every federal district court in the country.
Wound care fraud enforcement is concentrated in the District of Arizona (Apex prosecution), the Southern District of Florida (Vohra settlement, Strike Force), the Southern District of Georgia, and Strike Force districts including the Central District of California, the Southern District of Texas, and the Eastern District of New York. DOJ has signaled that enforcement will expand to additional districts.
Scott Armstrong and Drew Bradylyons have tried healthcare fraud cases and handled investigations in Strike Force districts and federal courts across the country. The firm is based in Washington, D.C. and represents clients in every jurisdiction where DOJ, CMS, and HHS-OIG investigate and prosecute wound care fraud cases.